COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA...BACTERIAL PNEUMONIA At Nabriva, we are developing brand new...
1
NEW TREATMENTS FOR CABP ARE NEEDED Anmicrobial resistance is one of our most serious health threats. 6 PNEUMONIA IS AN INFECTION OF THE LUNGS Community-acquired bacterial pneumonia (CABP) is among the most common types of pneumonia. COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA At Nabriva, we are developing brand new classes of anbiocs to treat serious infecons. LEARN MORE AT NABRIVA.COM 5 million cases per year 1 A leading cause of infecon-related death in the U.S. 5 COMMON DEADLY Approximately $17 billion in hospital costs per year 4 COSTLY 5th leading cause of hospitalizaon 2 Paents stay an average of 7 days 3 SERIOUS Certain bacteria that cause CABP have become resistant to one common anbioc at a rate on average of 50%. 7 U.S. FDA has issued mulple warnings about one current class of CABP treatments called fluoroquinolones. 8 It’s been nearly 20 years since a new class of anbiocs was available for CABP. 9,10 New anbiocs that kill bacteria in a different way are essenal to addressing the public health challenge of anmicrobial resistance. 11 PM-US-CORP-XXXXX © 2019 Nabriva Therapeucs US, Inc. 1. Brar N, Niederman M. Management of community-acquired pneumonia: a review and update. Ther Adv Respir Dis. 2011;5(1) 61-78. Doi: 10.1177/1753465810381518. 2. HCUP Fast Stats—Most common diagnoses for inpaent stays, 2015. hps://www.hcupus.ahrq.gov/faststats/NaonalDiagnosesServlet. Accessed July 23, 2019. 3. Sato R., Community-Acquired Pneumonia Episode Costs by Age and Risk in Commercially Insured US Adults Aged ≥50 Years. Appl Health Econ Health Policy 2013: 11:251- 258. doi:10.1007/s40258-013-0026-0. 4. American Lung Associaon Epidemiology and Stascs Unit Research and Health Educaon Division. Trends in Pneumonia and Influenza Morbidity and Mortality. November 2015. hp://www.lung.org/assets/documents/research/pi-trend-report.pdf. Accessed August 21, 2017. 5. Centers for Disease Control and Prevenon. Naonal Vital Stascs Reports, Vol. 68, No 9, June 24, 2019. Deaths: Final Data for 2017. hps://www.cdc.gov/nchs/data/ nvsr/nvsr68/nvsr68_09-508.pdf. Accessed July 23, 2019. 6. Tackling drug-resistant infecons globally: final report and recommendaons. Review on Anmicrobial Resistance, 2016. P10 7. Classi P, Landsman-Blumberg P, Carroll C, et al. The relaonship between macrolide-resistant streptococcus pneumoniae and treatment failure in adults with community-acquired pneumonia by CDC region in the United States. Abstract J03. In: Meeng abstracts, Academy of Managed Care Pharmacy Nexus 2016; October 3-6, 2016; Naonal Harbor, MD. 8. Food and Drug Administraon. FDA updates warnings for fluoroquinolone anbiocs on risks of mental health and low blood sugar adverse reacons. hps://www.fda.gov/ news-events/press-announcements/fda-updates-warnings-fluoroquinolones-anbiocs-risks-mentalhealth-and-low-blood-sugar-adverse. Accessed July 23, 2019. 9. Coates A, Halls G, Hu Y. Novel classes of anbiocs or more of the same?. Brish Journal of Pharmacology. 2011 Jan; 163: 190. 10. ZYVOX [package insert]. New York, NY: Pfizer Inc. January 2018. hp://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=649 (Accessed July 31, 2019) 11. Centers for Disease Control and Prevenon. Anbioc Resistance Threats in the United States, 2013, US Department of Health and Human Services.
Transcript of COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA...BACTERIAL PNEUMONIA At Nabriva, we are developing brand new...
NEW TREATMENTS FOR CABP ARE NEEDEDAntimicrobial resistance is one of our most serious health threats.6
PNEUMONIA IS AN INFECTION OF THE LUNGSCommunity-acquired bacterial pneumonia (CABP) is among the most common types of pneumonia.
COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA
At Nabriva, we are developing brand new classes of antibiotics to treat serious infections.
LEARN MORE AT NABRIVA.COM
5 million cases per year1
A leading cause of infection-related death in the U.S.5
COMMON
DEADLY
Approximately $17 billion in hospital costs per year4
COSTLY
5th leading cause of hospitalization2
Patients stay an average of 7 days3
SERIOUS
Certain bacteria that cause CABP have become resistant to one common antibiotic at a
rate on average of 50%.7
U.S. FDA has issued multiple warnings about one current class of CABP treatments called fluoroquinolones.8
It’s been nearly 20 years since a new class of antibiotics was
available for CABP.9,10
New antibiotics that kill bacteria in a different way are essential to addressing
the public health challenge of antimicrobial resistance.11
PM-US-CORP-XXXXX© 2019 Nabriva Therapeutics US, Inc.
1. Brar N, Niederman M. Management of community-acquired pneumonia: a review and update. Ther Adv Respir Dis. 2011;5(1) 61-78. Doi: 10.1177/1753465810381518. 2. HCUP Fast Stats—Most common diagnoses for inpatient stays, 2015. https://www.hcupus.ahrq.gov/faststats/NationalDiagnosesServlet. Accessed July 23, 2019. 3. Sato R., Community-Acquired Pneumonia Episode Costs by Age and Risk in Commercially Insured US Adults Aged ≥50 Years. Appl Health Econ Health Policy 2013: 11:251-
258. doi:10.1007/s40258-013-0026-0. 4. American Lung Association Epidemiology and Statistics Unit Research and Health Education Division. Trends in Pneumonia and Influenza Morbidity and Mortality. November
2015. http://www.lung.org/assets/documents/research/pi-trend-report.pdf. Accessed August 21, 2017. 5. Centers for Disease Control and Prevention. National Vital Statistics Reports, Vol. 68, No 9, June 24, 2019. Deaths: Final Data for 2017. https://www.cdc.gov/nchs/data/
nvsr/nvsr68/nvsr68_09-508.pdf. Accessed July 23, 2019. 6. Tackling drug-resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance, 2016. P10 7. Classi P, Landsman-Blumberg P, Carroll C, et al. The relationship between macrolide-resistant streptococcus pneumoniae and treatment failure in adults with community-acquired
pneumonia by CDC region in the United States. Abstract J03. In: Meeting abstracts, Academy of Managed Care Pharmacy Nexus 2016; October 3-6, 2016; National Harbor, MD. 8. Food and Drug Administration. FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions. https://www.fda.gov/
news-events/press-announcements/fda-updates-warnings-fluoroquinolones-antibiotics-risks-mentalhealth-and-low-blood-sugar-adverse. Accessed July 23, 2019. 9. Coates A, Halls G, Hu Y. Novel classes of antibiotics or more of the same?. British Journal of Pharmacology. 2011 Jan; 163: 190. 10. ZYVOX [package insert]. New York, NY: Pfizer Inc. January 2018. http://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=649 (Accessed July 31, 2019) 11. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013, US Department of Health and Human Services.
![Comparative Regional Analysis of Bacterial Pneumonia ...Failure (CHF) and Bacterial Pneumonia [1] have recorded high re-admission rates reflecting discrepancies in medical procedures.](https://static.fdocuments.in/doc/165x107/5ebb9879318fa16d813750c8/comparative-regional-analysis-of-bacterial-pneumonia-failure-chf-and-bacterial.jpg)
